Back to Search
Start Over
Targeting CD40-Induced TRAF6 Signaling in Macrophages Reduces Atherosclerosis
- Source :
- Journal of the American College of Cardiology, 71(5), 527-542. Elsevier Science, Journal of the American College of Cardiology, Journal of the American College of Cardiology, 71(5), 527-542, Journal of the American College of Cardiology, 71, 5, pp. 527-542, Journal of the American College of Cardiology, 71(5), 527-542. Elsevier USA, Seijkens, T T P, van Tiel, C M, Kusters, P J H, Atzler, D, Soehnlein, O, Zarzycka, B, Aarts, S A B M, Lameijer, M, Gijbels, M J, Beckers, L, den Toom, M, Slütter, B, Kuiper, J, Duchene, J, Aslani, M, Megens, R T A, van ‘t Veer, C, Kooij, G, Schrijver, R, Hoeksema, M A, Boon, L, Fay, F, Tang, J, Baxter, S, Jongejan, A, Moerland, P D, Vriend, G, Bleijlevens, B, Fisher, E A, Duivenvoorden, R, Gerdes, N, de Winther, M P J, Nicolaes, G A, Mulder, W J M, Weber, C & Lutgens, E 2018, ' Targeting CD40-Induced TRAF6 Signaling in Macrophages Reduces Atherosclerosis ', Journal of the American College of Cardiology, vol. 71, no. 5, pp. 527-542 . https://doi.org/10.1016/j.jacc.2017.11.055, https://doi.org/10.1016/j.jacc.2017.11.055, Journal of the American College of Cardiology, 71, 527-542
- Publication Year :
- 2018
-
Abstract
- Background Disrupting the costimulatory CD40-CD40L dyad reduces atherosclerosis, but can result in immune suppression. The authors recently identified small molecule inhibitors that block the interaction between CD40 and tumor necrosis factor receptor-associated factor (TRAF) 6 (TRAF-STOPs), while leaving CD40-TRAF2/3/5 interactions intact, thereby preserving CD40-mediated immunity. Objectives This study evaluates the potential of TRAF-STOP treatment in atherosclerosis. Methods The effects of TRAF-STOPs on atherosclerosis were investigated in apolipoprotein E deficient (Apoe−/−) mice. Recombinant high-density lipoprotein (rHDL) nanoparticles were used to target TRAF-STOPs to macrophages. Results TRAF-STOP treatment of young Apoe−/− mice reduced atherosclerosis by reducing CD40 and integrin expression in classical monocytes, thereby hampering monocyte recruitment. When Apoe−/− mice with established atherosclerosis were treated with TRAF-STOPs, plaque progression was halted, and plaques contained an increase in collagen, developed small necrotic cores, and contained only a few immune cells. TRAF-STOP treatment did not impair “classical” immune pathways of CD40, including T-cell proliferation and costimulation, Ig isotype switching, or germinal center formation, but reduced CD40 and β2-integrin expression in inflammatory monocytes. In vitro testing and transcriptional profiling showed that TRAF-STOPs are effective in reducing macrophage migration and activation, which could be attributed to reduced phosphorylation of signaling intermediates of the canonical NF-κB pathway. To target TRAF-STOPs specifically to macrophages, TRAF-STOP 6877002 was incorporated into rHDL nanoparticles. Six weeks of rHDL-6877002 treatment attenuated the initiation of atherosclerosis in Apoe−/− mice. Conclusions TRAF-STOPs can overcome the current limitations of long-term CD40 inhibition in atherosclerosis and have the potential to become a future therapeutic for atherosclerosis.<br />Central Illustration
- Subjects :
- 0301 basic medicine
Apolipoprotein E
MECHANISM
rHDL, recombinant high-density lipoprotein
Cell Culture Techniques
030204 cardiovascular system & hematology
PHENOTYPE
THERAPY
Monocytes
ACTIVATION
immunology
Mice
DC, dendritic cell
0302 clinical medicine
Cell Movement
TRAF, tumor necrosis factor receptor-associated factor
CD40
Medicine
Propiophenones
Aniline Compounds
biology
nanotechnology
NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells
BMDM, bone marrow-derived macrophage
Plaque, Atherosclerotic
3. Good health
medicine.anatomical_structure
Apoe, apolipoprotein E
Tumor necrosis factor alpha
medicine.symptom
Cardiology and Cardiovascular Medicine
CD40-TRAF6 INTERACTIONS
Signal Transduction
Bioinformatics
CD40 Ligand
INHIBITION
Inflammation
CVD, cardiovascular disease
Article
03 medical and health sciences
Immune system
Animals
Humans
TNF Receptor-Associated Factor 6
SMI, small molecule inhibitor
business.industry
Monocyte
Macrophages
Germinal center
drug development
Mice, Inbred C57BL
Disease Models, Animal
030104 developmental biology
Immunoglobulin class switching
inflammation
CELLS
Cancer research
biology.protein
IMMUNE-SYSTEM
atherosclerosis
business
Nanomedicine Radboud Institute for Molecular Life Sciences [Radboudumc 19]
Subjects
Details
- Language :
- English
- ISSN :
- 07351097
- Database :
- OpenAIRE
- Journal :
- Journal of the American College of Cardiology, 71(5), 527-542. Elsevier Science, Journal of the American College of Cardiology, Journal of the American College of Cardiology, 71(5), 527-542, Journal of the American College of Cardiology, 71, 5, pp. 527-542, Journal of the American College of Cardiology, 71(5), 527-542. Elsevier USA, Seijkens, T T P, van Tiel, C M, Kusters, P J H, Atzler, D, Soehnlein, O, Zarzycka, B, Aarts, S A B M, Lameijer, M, Gijbels, M J, Beckers, L, den Toom, M, Slütter, B, Kuiper, J, Duchene, J, Aslani, M, Megens, R T A, van ‘t Veer, C, Kooij, G, Schrijver, R, Hoeksema, M A, Boon, L, Fay, F, Tang, J, Baxter, S, Jongejan, A, Moerland, P D, Vriend, G, Bleijlevens, B, Fisher, E A, Duivenvoorden, R, Gerdes, N, de Winther, M P J, Nicolaes, G A, Mulder, W J M, Weber, C & Lutgens, E 2018, ' Targeting CD40-Induced TRAF6 Signaling in Macrophages Reduces Atherosclerosis ', Journal of the American College of Cardiology, vol. 71, no. 5, pp. 527-542 . https://doi.org/10.1016/j.jacc.2017.11.055, https://doi.org/10.1016/j.jacc.2017.11.055, Journal of the American College of Cardiology, 71, 527-542
- Accession number :
- edsair.doi.dedup.....cca6a3b34a4eaed1e2703cd007d5bc8d
- Full Text :
- https://doi.org/10.1016/j.jacc.2017.11.055